News | June 3, 2024

Partex And Singapore's Experimental Drug Development Centre Collaborate To Bring Forward An Innovative Approach For Early Drug Discovery And Development

Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR).

The parties will initially use Partex’ technologies, under its Asset Exchange platform, to identify novel indications with associated clinical paths and markets for EDDC’s portfolio assets. The parties intend to broaden this partnership to combine AI technology, scientific expertise and wet lab validations to accelerate the progress of new drug discovery programs. Partex will bring its industry validated, AI-powered in-silico platform for novel target identification, de novo molecule generation, as well as structure-activity relationship (SAR) and optimization across small and large molecules. The partners will also leverage Partex’s proprietary knowledge graph, small molecule screening library and real world data. EDDC will bring substantial expertise and experience in a full range of drug discovery and development capabilities from initial discovery through clinical proof-of-concept.

“At Partex, we stand at the cusp of Artificial Intelligence and translational medicine to transform the pace of new drug discovery. Our collaboration with EDDC will allow us to integrate lab driven experimental data from state-of-the-art facilities to train, optimize and validate AI models and rapidly prove new hypothesis.” said Dr. Gunjan Bhardwaj, Founder of Partex. “Together with EDDC we envision bringing forward promising therapeutic candidates for unmet indications.”

“EDDC’s mission is to translate innovative scientific discoveries into great medicines. Partnering with Partex allows us to leverage cutting-edge AI technology alongside our comprehensive drug discovery and development expertise,” said Prof Damian O’Connell, Chief Executive Officer of EDDC. “Together, we are poised to accelerate the journey from groundbreaking research to life-changing treatments, addressing diseases with critical unmet needs.”

Source: Partex